BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review


7/13/2009 8:49:06 AM

SAN DIEGO, July 13 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Victory's lead investigational rug, MGX006. If approved, MGX006 will provide patients and healthcare providers the advantage of a proven antiemetic agent combined with a proprietary formulation ideally suited for the treatment of nausea and vomiting.

Approximately 25 million prescriptions are written annually in the U.S. for anti-emetic therapeutics. The vast majority of these prescriptions are for traditional, oral solid drug formulations, which can be problematic among patients with emesis.

About Victory Pharma

Founded in 2003, Victory Pharma, Inc. is a privately held specialty pharmaceutical company headquartered in San Diego, CA focused on acquiring, developing, and marketing products to treat pain and related conditions. Victory markets its lead product, NAPRELAN(R) (naproxen sodium) Controlled-Release Tablets and other pain products to pain management specialists, rheumatologists, orthopedic surgeons, and selected primary care physicians through its physician office-based field sales force. Victory is also developing proprietary products for the treatment of chronic pain and common opiate- induced side effects Further information regarding Victory Pharma is available at www.victorypharma.com.

SOURCE Victory Pharma, Inc.

CONTACT: David J. Parker, Chief Financial Officer of Victory Pharma, Inc.,
+1-858-720-4524

Web site: http://www.victorypharma.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES